American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis

Handelsman, Yehuda, Henry, Robert R., Bloomgarden, Zachary T., Dagogo-Jack, Sam, DeFronzo, Ralph A., Einhorn, Daniel, Ferrannini, Ele, Fonseca, Vivian A., Garber, Alan J., Grunberger, George, LeRoith, Derek, Umpierrez, Guillermo E., Weir, Matthew R.·2016·Endocrine Practice
DOI 10.4158/ep161292.ps

Cited by (359)

Items 301–359 of 359

  1. Diabetic Ketoacidosis Linked with Sodium Glucose Co-Transporter 2 Inhibitors in an Elderly Patient with Type 2 Diabetes
    José G. Jiménez-Montero · 2019 · International Journal of Endocrinology and Metabolic Disorders
  2. Continuous glucose monitoring - proved hypoglycemia in sodium-glucose co-transporter-2 inhibitors - treated type 2 diabetes patients: a link to ketosis development
    Shmuel Levit, Shmuel M. Giveon, Ildar N. Musin, Royi Barnea, Ifat Korek-Abadi, Vyacheslav Moiseevich Levit, Darian Ryder, Chen Hanna Ryder · 2019 · Pharmacy Formulas
  3. Introduction: Clinical Emergency During Aesthetic Procedures
    Merces Assumpcao‐Morales, Javier Morales · 2020 · Springer eBooks
  4. Endocrine Emergencies in the ICU
    Beranton Whisenant · 2020 · Springer eBooks
  5. SGLT2-inhibitor and its place in Contemporary Diabetes Management
    Chin Meng Khoo · 2020 · The Singapore Family Physician
  6. A stepwise approach for pharmacists: Cardiovascular risk reduction with novel antihyperglycemic agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease
    Logan Underwood, William Semchuk, Lori Albers · 2020 · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada
  7. Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?
    Zay Myo Htet, Mahzuz Karim · 2021 · Journal of the Royal Society of Medicine
  8. Glycemic Considerations for Tests and Procedures
    Makeda Dawkins, Marcel Souffrant, Alyson K. Myers · 2021 · Elsevier eBooks
  9. Inhibiteurs du SGLT2 : que des bénéfices ?
    Lucie Sciotto, François R. Jornayvaz · 2021 · JMIG
  10. Type 2 diabetes: glycaemic control
    David Levy MD FRCP · 2017 · Wiley eBooks
  11. INHIBITION OF SODIUM GLUCOSE TRANSPORT PROTEIN 2: CLINICAL AND PHARMACOLOGICAL EFFECTS IN CHRONIC HEART FAILURE
    Genshat S. Galyautdinov, Alexander G. Zhidyaevskij, Maria K. Nesterina, Карина Рустемовна Миннегалимова · 2022 · The Bulletin of Contemporary Clinical Medicine
  12. Important Dietary Considerations for Sodium-Glucose Cotransporter 2 Inhibitors
    Angelina Anthamatten · 2023 · The Journal for Nurse Practitioners
  13. Diabetes and Heart Failure
    Angelina Anthamatten · 2023 · Springer eBooks
  14. Choice of Therapy in Obese Type 2 Diabetes
    VivekaP Jyotsna, Shweta Deshmukh · 2022 · Chronicle of Diabetes Research and Practice
  15. 53-Year-Old Man With Dyspnea
    Benjamin R Stultz, Matthew W. Ewy, Sarah J. Chalmers · 2023 · Mayo Clinic Proceedings
  16. PRO: Should Patients Taking Sodium-Glucose Co-Transporter 2 Inhibitors Be Dropped From the Elective Surgical Program?
    Sylvia Ryz, Clara Castellucci · 2024 · Journal of Cardiothoracic and Vascular Anesthesia
  17. An Overview on Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors Induced Euglycemic Diabetic Ketoacidosis: Clinical Manifestation, Mechanism, Diagnosis, Prevention and Treatment
    R Aakash, S Prathap, S Deepak Raj, P T Dharshne, Neena Priyamalar EM · 2024 · International Journal of Pharma Professional’s Research (IJPPR)
  18. Euglycemic Diabetic Ketoacidosis—A Rare Cause for Delayed Extubation: Case Report
    Marutheesh Mallappa, Gayathri K Reddy, Murali Jayaraman · 2024 · Indian Journal of Critical Care Case Report
  19. Cetoacidosis diabética
    José Correa-Guerrero, Jesus David Bello Simanca, Rafael Guillermo Betancurt Mendoza, Luis Rodríguez Arrieta, Alejandro Alberto Castellanos Pinedo, Carmelo Rafael Dueñas Castell · 2024 · Acta Colombiana de Cuidado Intensivo
  20. SGLT-2 inhibitors and high-dose acarbose as potential high-risk combinations for ketosis and ketoacidosis in Asian patients with T2DM: A case series
    Hui Guo · 2024 · Journal of Clinical Images and Medical Case Reports
  21. Pulmoner Emboli
    Hüseyin Furkan Küçükbezirci · 2024
  22. Akut Karaciğer Yetmezliği ve Hepatik Ensefalopati
    Gökcan Aman · 2024
  23. Zehirlenmelere İlk Yaklaşım
    Yunus Çirkin, Seda Özkan · 2024
  24. Parasetamol Zehirlenmesi
    Mehmet Gün · 2024
  25. Hemorajik İnme
    Sevil Kuşku KIYAK · 2024
  26. Status Epileptikus
    Hüseyin Furkan Küçükbezirci, Fatih ÇAKMAK · 2024
  27. Akut Solunum Yetmezliği
    Seda ÖZKAN · 2024
  28. Çoklu Travmaya Yaklaşım
    Altuğ Kanbakan · 2024
  29. Metil Alkol Zehirlenmesi
    Seda Özkan · 2024
  30. Akut Böbrek Yetmezliği (Akut Böbrek Hasarı)
    Sevil Kuşku KIYAK · 2024
  31. Crush Yaralanma (Ezilme Sendromu) ve Rabdomiyoliz
    Afşın İPEKCI · 2024
  32. Karın Travmaları
    Sevil Kuşku KIYAK · 2024
  33. Akut Bilinç Değişikliği
    Türker DEMIRTAKAN · 2024
  34. Kafa Travması
    Gökcan Aman · 2024
  35. Akut İskemik İnme ve Geçici İskemik Atak
    Sevil Kuşku KIYAK · 2024
  36. Medicações inibidoras de SGLT2 e sua relação com a cetoacidose diabética: uma revisão a luz da literatura
    Juliana Borges Oliveira Cano, Rodrigo Borges Oliveira Cano · 2024 · Brazilian Journal of Health Review
  37. Diabetic Ketoacidosis
    Hatice Şeyma Akça · 2023
  38. Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure
    Yifei Zhang, Yu-Xiang Liu, Wuxiao Yang · 2025 · World Journal of Cardiology
  39. Euglycemic Diabetic Ketoacidosis Due to Sodium–Glucose Cotransporter 2 Inhibitor Use
    Diana Soliman, Nicole E. Jelesoff · 2021
  40. Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis in a Recipient of Concurrent Pancreas-Kidney Transplantation With Type 1 Diabetes Mellitus
    Takahiro Kawaji, Tsukasa Jinno, S Komatsu, Naohide Kuriyama, Tomoyuki Nakamura · 2025 · Cureus
  41. Sodium-Glucose Cotransporter-2 Inhibitors
    Helen D Berlie · 2025 · American Diabetes Association eBooks
  42. Low-carbohydrate diets in diabetes mellitus: A clinical case report and a brief literature review
    N. V. Hudiakova, Yu. S. Khudyakov, Ivan Yu. Pchelin, S. Stojanovich, D. Radoičić, N. Yu. Semigolovskii, С. О. Мазуренко, Виктор Владимирович Смирнов · 2025 · Meditsinskiy sovet = Medical Council
  43. Additional file 2 of Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature
    Daniele Sartori, Aronson, Jeffrey K., Onakpoya, Igho J. · 2020 · Figshare
  44. Additional file 1 of Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature
    Daniele Sartori, Aronson, Jeffrey K., Onakpoya, Igho J. · 2020 · Figshare
  45. Empagliflozin-associated euglycemic ketoacidosis
    Ivona Vranić, Ivan Stanković, Miloš Panić, Predrag Miličević, Aleksandar Nešković · 2022 · Srce i krvni sudovi
  46. Agentes antidiabéticos de nueva generación en cirugía cardíaca: beneficios cardiovasculares y renales más allá del control glucémico
    Viviana Beatriz Tinizhañay Peralta · 2026 · Cirugía Cardiaca en México
  47. Primer caso reportado en Perú de cetoacidosis euglicémica por inhibidor del cotransportador de sodio glucosa tipo 2
    José Paz‐Ibarra, Juan Eduardo Quiroz Aldave, María del Carmen Durand‐Vásquez, Luis Alberto Concepción Urteaga, Rommy Díaz Quispe, Marcio José Concepción‐Zavaleta · 2025 · Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
  48. Just the facts: sodium–glucose cotransporter-2 inhibitor-associated diabetic ketoacidosis
    Kavish Chandra, Liam D Walsh, Paul Atkinson · 2026 · Canadian Journal of Emergency Medicine
  49. Hidden risk of euglycemic diabetic ketoacidosis with sodium-glucose cotransporter 2 (SGLT2) inhibitors in emergency general surgery in the United States: a case report
    Laura Roberson, June Yao, Christina So, Brian Tuai · 2026 · JOURNAL OF ACUTE CARE SURGERY
  50. Evaluation of SGLT2 inhibitor effects on glycemic management in hospitalized non-critically ill patients
    E.J. Marineau, Dennis Dubovetsky · 2026 · JAPhA Practice Innovations
  51. From molecules to the clinic—pathophysiology of sodium-glucose cotransporter 2 inhibitors and their emerging role in urology: A comprehensive review from the European Association of Urology Section of Endourology
    A. Talyshinskii, V. Gauhar, Steffi Kar Kei Yuen, Selçuk Güven, T. Tokas, A. Tsaturyan, Dmitry Enikeev, B. Somani · 2026 · Asian Journal of Urology
  52. Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Observational Studies
    Nisrine Haddad, Nawal Farhat, Christopher A. Gravel, Yue Chen, Franco Momoli, Donald R. Mattison, Jeannette Goguen, Daniel R. Krewski · 2026 · Journal of Clinical Medicine
  53. Role of the kidney in glucose homeostasis: the basis for pharmacotherapy and prevention of cardiorenal complications in diabetes
    Eugênio Cersósimo, Ralph A. DeFronzo · 2026 · Kidney International
  54. Comparative Study of Dehydroepiandrosterone versus Femarelle® on Menopausal Systemic and Genitourinary Syndrome
    Cheng‐Yu Long, Chih‐Cheng Huang, Chieh‐Yu Chang, Zi-Xi Loo, Chien‐Wei Feng, I-Chieh Sung, Kun‐Ling Lin · 2026 · Gynecologic and Obstetric Investigation
  55. SGLT-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Masked by Concurrent Pneumoperitoneum Following Spinal Surgery Under General Anesthesia: A Case Report
    Minju Kim, Jiyoon Bhan, Do Gyeong Lee, Hyun Sik Chung · 2026 · Journal of Clinical Medicine
  56. Disproportionate reporting of euglycaemic and diabetic ketoacidosis with SGLT-2 inhibitors across expanding cardiorenal indications: a cross-database study of FAERS and JADER
    Jinqian Chen, Deyin Wang, Xiaochuan Duan, Jianbo Wang, Zhenyu Zhao, Xiaolong Xing · 2026 · Frontiers in Endocrinology
  57. Euglycemic Diabetic Ketoacidosis: An Evolving Landscape in Diabetes Complications and Diagnostic Challenges—A Narrative Review
    Shubha Jayaram, Aayush Jain, Swetha Nagarahalli Kempegowda, Sachin Sreenath, Lakshmi Nagendra, Deepa Krishna, Sumaiya Anjum · 2026 · Indian Journal of Medical Biochemistry
  58. Perioperative management of GLP-1 receptor agonists and SGLT2 inhibitors: An updated review for anesthesiologists
    Amer Majeed, Rashid Amir, Sajjad Rasool, Arshad Mahmood · 2026 · Saudi Journal of Anaesthesia
  59. Empagliflozin’s role in cardiometabolic disease treatment: an Egyptian expert’s view
    Samir Helmy Assaad Khalil, Fawzy Elmessallamy, Khaled Elsayed Elhadidy, Mohamed Hesham Mohamed Fahmy El Hefnawy, Mohamed Reda Halawa, Mohamed Zeitoun, Shady Hussein, Ibrahim Elebrashy · 2026 · Diabetology & Metabolic Syndrome